FibroBiologics expands its fibroblast-based therapeutic platform into Hantavirus pulmonary syndrome (HPS), advancing preclinical research focused on cytokine modulation, endothelial repair, and inflammatory lung injury in a disease with no approved therapies.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
FibroBiologics announced a strategic expansion of its fibroblast-based therapeutic platform into Hantavirus pulmonary syndrome (HPS), a rare but severe viral respiratory disease with mortality rates exceeding 35–40% and no approved disease-modifying therapies.
Building on ongoing preclinical work in acute respiratory distress syndrome (ARDS), the company highlighted mechanistic similarities between severe HPS and COVID-19-related ARDS, including uncontrolled inflammation, endothelial dysfunction, pulmonary edema, and progressive lung damage.
HPS, transmitted primarily through exposure to infected rodents, is most prevalent in the Americas and can rapidly progress to respiratory failure, multi-organ dysfunction, and death. Survivors often face long-term pulmonary complications such as fibrosis and impaired lung function.
FibroBiologics’ fibroblast platform is designed to modulate inflammatory signaling, restore endothelial barrier integrity, and support tissue regeneration. In ARDS models, fibroblasts reduced excessive cytokine responses and improved tissue repair, effects the company believes may translate to HPS.
The company is currently evaluating its fibroblast platform in Hantavirus disease models, focusing on cytokine modulation and reducing endothelial permeability. Exploratory discussions with regulatory authorities are planned to assess a potential clinical development pathway, including opportunities for orphan drug designation.
CEO Pete O’Heeron emphasized that HPS represents a significant unmet medical need, noting the severity of respiratory complications and lack of available therapies. He stated that FibroBiologics’ fibroblast platform may help address cytokine-driven inflammation and lung tissue damage observed in both HPS and ARDS.
References
About the Writer
Mahathi Palivela (LinkedIn) is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.